Ocera Therapeutics, Inc. (OCRX) Stock Rating Lowered by Zacks Investment Research
Ocera Therapeutics, Inc. (NASDAQ:OCRX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “Ocera Therapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver diseases. Ocera Therapeutics, Inc., formerly known as Tranzyme, Inc., is based in San Diego, California. “
Ocera Therapeutics (NASDAQ:OCRX) opened at 1.11 on Wednesday. Ocera Therapeutics has a 52 week low of $0.52 and a 52 week high of $3.07. The company has a 50-day moving average of $1.02 and a 200 day moving average of $1.13. The company’s market cap is $29.43 million.
Ocera Therapeutics (NASDAQ:OCRX) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.01. On average, equities analysts forecast that Ocera Therapeutics will post ($1.20) EPS for the current fiscal year.
Institutional investors have recently bought and sold shares of the company. Hikari Power Ltd lifted its holdings in shares of Ocera Therapeutics by 50.6% during the 2nd quarter. Hikari Power Ltd now owns 376,596 shares of the biopharmaceutical company’s stock worth $437,000 after acquiring an additional 126,596 shares during the last quarter. Virtu KCG Holdings LLC grew its position in Ocera Therapeutics by 194.6% in the second quarter. Virtu KCG Holdings LLC now owns 213,531 shares of the biopharmaceutical company’s stock worth $248,000 after acquiring an additional 141,040 shares in the last quarter. Finally, Perceptive Advisors LLC purchased a new position in Ocera Therapeutics in the first quarter worth $2,817,000. Hedge funds and other institutional investors own 20.25% of the company’s stock.
About Ocera Therapeutics
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.